Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Preferred Bidder Status

4 Sep 2006 15:48

CareCapital Group plc04 September 2006 For immediate release, 4 September 2006 CareCapital Group Plc ("CareCapital" or "the Group") Joint-Venture Awarded Preferred Bidder Status CareCapital (AIM: CARE), a healthcare real estate developer and owner that wasadmitted to AIM on 4 August 2006, today announces that a joint-venture has beenawarded preferred bidder status for a new primary care centre in Flintshire,Wales. This will be CareCapital's first development in Wales. The Healthcare Property Company Wales Limited ("HPC Wales") has been selected aspreferred bidder for a major new primary care centre for the Flintshire HealthBoard in the town of Buckley. The new primary care centre will bring togetherunder one roof existing GP practices and community health services in a purposebuilt 4,000 sq.m. facility comprising a range of clinical and other patientsupport services including a pharmacy. The building has been designed to allowfor future flexibility and expansion to meet the changing healthcare needs ofthe local community. The total development cost of the facility will be approximately £6.5 million.It is anticipated construction works will commence in mid-March 2007 and theCentre opened to patients in early April 2008. The completed facility will beleased for an initial period of 20 years to the GP partnerships and theFlintshire Health Board at an initial rent of approximately £425,000 per annum. HPC Wales is a strategic joint venture between CareCapital (50%) and GaufronHealthcare Limited ("Gaufron") (50%). Gaufron is a well-established medicalcentre developer in Wales, based in Llandrindod Wells. Commenting, Paul Stacey - CareCapital's Managing Director - said "I am extremelypleased that we have been successful in being selected to develop this importanthealthcare facility in North Wales. We look forward to the opportunity to workwith the Flintshire Health Board and Welsh Health Estates to take this schemethrough to completion. I congratulate the bid team, including our colleaguesfrom Gaufron and the architects, Austin-Smith: Lord on the win againstsignificant competition. The Board hopes that our joint-venture with Gaufronwill be able to build on this success to become a leading developer ofhealthcare related properties in Wales." For further information please visit www.carecapital.co.uk or contact: Paul Stacey, Managing DirectorShareen Courtney, MarketingCareCapital Group PlcTel: 020 7034 1949pstacey@carecapital.co.ukscourtney@carecapital.co.uk Simon Hudson, Richard SunderlandTavistock CommunicationsTel: 020 7920 3150shudson@tavistock.co.uk/rsunderland@tavistock.co.uk Lindsay Mair, Director - Corporate FinanceDaniel Stewart & Co. PlcTel: 020 7776 6550lindsay.mair@danielstewart.co.uk This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
27th Aug 20197:00 amRNSTotal Voting Rights and Directors' Shareholdings
8th Aug 201910:45 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Nearing the end-goal
7th Aug 20197:00 amRNSIssue of equity and new debt facility
6th Aug 201911:05 amRNSSecond Price Monitoring Extn
6th Aug 201911:00 amRNSPrice Monitoring Extension
25th Jul 20195:12 pmRNSResult of AGM
25th Jul 20197:00 amRNSAGM Statement & Technological update
22nd Jul 20197:00 amRNSHarley Street update
28th Jun 20197:00 amRNSFinal Results
3rd Jun 20197:00 amRNSTechnological update
31st May 20195:30 pmRNSTotal Voting Rights
17th May 20195:29 pmRNSHolding(s) in Company
16th May 20192:23 pmEQSAdvanced Oncotherapy (AVO-GB): Strong fundamentals underpin future growth
13th May 201912:20 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Commercialising a breakthrough technology
10th May 20197:00 amRNSDebt facility secured
16th Apr 201910:26 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Preparing for commercialisation
16th Apr 20199:12 amEQSAdvanced Oncotherapy (AVO-GB): Key talent acquisition reaffirms the promise of LIGHT
16th Apr 20197:00 amRNSSenior Management Appointment
7th Mar 20199:00 amRNSPrice Monitoring Extension
22nd Feb 20197:00 amRNSGrant of options
1st Feb 20197:00 amRNSAppointment of Nominated Adviser and Joint Broker
30th Jan 201911:45 amRNSSchedule 2(g) Disclosure
29th Jan 20199:38 amRNSTotal Voting Rights and Significant Shareholdings
24th Jan 201912:14 pmRNSSchedule 2(g) Disclosure
22nd Jan 20193:29 pmRNSResult of General Meeting
21st Jan 201911:15 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Important regulatory milestone: ISO approval
21st Jan 20197:00 amRNSISO 13485:2016 certification for medical devices
21st Dec 201810:15 amRNSLaunch of 2018 SAYE Scheme
21st Dec 20187:00 amRNSProposed Direct Subscription to raise £10.0m
16th Oct 20184:31 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Four components integrated
16th Oct 20183:58 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Treatment planning system agreement
10th Oct 20187:30 amRNSGPSL Research - Flash Note on AVO
10th Oct 20187:00 amRNSTechnological update
4th Oct 201811:07 amRNSGPSL Research - Flash Note on AVO
28th Sep 20187:00 amRNSHalf-year Report
27th Sep 20187:00 amRNSTechnological update
10th Sep 201811:32 amRNSHolding(s) in Company
7th Sep 201811:52 amRNSHolding(s) in Company
3rd Sep 20185:15 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Treatment planning system agreement
3rd Sep 201811:38 amRNSCompletion of the £6.41m Placing
29th Aug 20189:57 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Treatment planning system agreement
28th Aug 20187:00 amRNSDirector Declaration
9th Aug 20187:00 amRNSExercise of Warrants and Issue of Shares
2nd Aug 20187:00 amRNS£6.41m Placing
25th Jul 20183:34 pmRNSResult of AGM
4th Jul 20184:40 pmRNSSecond Price Monitoring Extn
4th Jul 20184:35 pmRNSPrice Monitoring Extension
4th Jul 201811:05 amRNSSecond Price Monitoring Extn
4th Jul 201811:00 amRNSPrice Monitoring Extension
4th Jul 20189:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.